---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-26-000055"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2026-08-13T20:06:49+00:00"
generated_at: "2026-08-13T20:09:27.087896+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Elicio Q2 net loss $8.2M; Phase 2 AMPLIFY-7P trial misses primary endpoint

## Summary
- Phase 2 AMPLIFY-7P trial of ELI-002 7P in adjuvant mKRAS pancreatic cancer did not meet primary endpoint; evaluating R0 resected subgroup for Phase 3 strategy.
- Q2 2026 net loss $8.2M ($0.43/share) vs $10.6M ($0.66/share) in Q2 2025; R&D expense $6.8M, G&A $3.6M.
- Cash $23.5M at June 30, 2026; July 2026 $15.0M registered direct offering; runway into Q1 2027.
- Plans Phase 1 combo study of ELI-002 7P + RAS inhibitor ± anti-PD-1 in metastatic pancreatic cancer, Q4 2026; multiple complete responses observed.
- MSK-led Phase 1 neoadjuvant trial of ELI-002 7P + chemo + checkpoint inhibition activated.

## SEC filing metadata
- accession: 0001601485-26-000055
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2026-08-13T20:06:49+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000055/0001601485-26-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000055/eltx-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-26-000055
- JSON: https://secwatch.observer/filing/0001601485-26-000055.json
- Plain text: https://secwatch.observer/filing/0001601485-26-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.